Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?

References

• Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010;51(5):1675-82
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011;106(9):1646-53
   PubMed Web of Science ®Google Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the european association for the study of the liver. Hepatology 2014;60(2):715-35
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Olde Damink SW, Butterworth RF, et al. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005;20(3):169-79
   PubMed Web of Science ®Google Scholar
• Bernal W, Hall C, Karvellas C, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007;46(6):1844-52
   PubMed Web of Science ®Google Scholar
• Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM 2006;8(6):433-5
   PubMedGoogle Scholar
• Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011;54(4):640-9
   PubMed Web of Science ®Google Scholar
• Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005;38(8):696-9
   PubMed Web of Science ®Google Scholar
• Shawcross D, Davies N, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40(2):247-54
   PubMed Web of Science ®Google Scholar
• Jalan R, Olde Damink SW, Hayes PC, et al. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol 2004;41(4):613-20
   PubMed Web of Science ®Google Scholar
• Wright G, Davies N, Shawcross D, et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007;45(6):1517-26
   PubMed Web of Science ®Google Scholar
• Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001;34(1):32-7
   PubMed Web of Science ®Google Scholar
• Singh R, Bullard J, Kalra M, et al. Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin Immunol 2011;138(1):41-9
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60(5):940-7
   PubMed Web of Science ®Google Scholar
• Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513(7516):59-64
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013;8(4):e60042
   PubMed Web of Science ®Google Scholar
• Berry PA, Antoniades CG, Carey I, et al. Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med 2011;37(3):453-60
   PubMed Web of Science ®Google Scholar
• Taylor NJ, Manakkat Vijay GK, Abeles RD, et al. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther 2014;40(6):705-15
   PubMed Web of Science ®Google Scholar
• Shawcross D, Wright G, Stadlbauer V, et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008;48(4):1202-12
   PubMed Web of Science ®Google Scholar
• Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005;365(9457):431-3
   PubMed Web of Science ®Google Scholar
• Prasad S, Dhimna R, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-59
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Gluud L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. Br Med J 2004;328:1046-50
   PubMed Web of Science ®Google Scholar
• Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014;59(3):1073-83
   PubMed Web of Science ®Google Scholar
• Bai M, He C, Yin Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther 2014;40(1):63-71
   PubMed Web of Science ®Google Scholar
• Kristiansen RG, Rose CF, Fuskevag OM, et al. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway. Am J Physiol Gastrointest Liver Physiol 2014;307(10):G1024-31
   Web of Science ®Google Scholar
• Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39(5):1441-9
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014;39(10):1113-25
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014;147(6):1327-37
   PubMed Web of Science ®Google Scholar
• Stadlbauer V, Mookerjee R, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008;48(6):945-51
   PubMed Web of Science ®Google Scholar